Key statistics
As of last trade Vaxcyte Inc (PCVX:NSQ) traded at 87.20, -27.97% below its 52-week high of 121.06, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 85.78 |
---|---|
High | 87.82 |
Low | 85.33 |
Bid | 87.06 |
Offer | 87.23 |
Previous close | 85.96 |
Average volume | 2.23m |
---|---|
Shares outstanding | 124.64m |
Free float | 121.98m |
P/E (TTM) | -- |
Market cap | 10.71bn USD |
EPS (TTM) | -4.55 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 15:54 GMT.
More ▼
- Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
- Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
- Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte Announces Pricing of $1.3 Billion Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte Appoints John Furey to Board of Directors
More ▼